# ![@canoebrookbl Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1341917218481860608.png) @canoebrookbl canoebrookbl

canoebrookbl posts on X about $qure, $xbi, $abvx, based the most. They currently have [---] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1341917218481860608/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:interactions.svg)

- [--] Week [-----] -83%
- [--] Month [------] -37%
- [--] Months [-------] +78,748%

### Mentions: [--] [#](/creator/twitter::1341917218481860608/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:posts_active.svg)

- [--] Week [--] -6.30%
- [--] Month [--] +2.40%
- [--] Months [---] +9,517%

### Followers: [---] [#](/creator/twitter::1341917218481860608/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:followers.svg)

- [--] Week [---] +0.36%
- [--] Month [---] +4.10%
- [--] Months [---] +258%

### CreatorRank: [-------] [#](/creator/twitter::1341917218481860608/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  23.08% [finance](/list/finance)  18.27% [technology brands](/list/technology-brands)  5.77% [social networks](/list/social-networks)  3.85% [exchanges](/list/exchanges)  0.96% [financial services](/list/financial-services)  0.96%

**Social topic influence**
[$qure](/topic/$qure) #22, [$xbi](/topic/$xbi) 12.5%, [$abvx](/topic/$abvx) #28, [based](/topic/based) 6.73%, [science](/topic/science) 5.77%, [if you](/topic/if-you) 5.77%, [strong](/topic/strong) 5.77%, [$bhvn](/topic/$bhvn) 5.77%, [$nvs](/topic/$nvs) 4.81%, [opinion](/topic/opinion) 4.81%

**Top accounts mentioned or mentioned by**
[@usfda](/creator/undefined) [@vprasadmdmph](/creator/undefined) [@potus](/creator/undefined) [@drmakaryfda](/creator/undefined) [@desertdweller93](/creator/undefined) [@youtube](/creator/undefined) [@alecgaffney](/creator/undefined) [@rarediseases](/creator/undefined) [@lauraloomer](/creator/undefined) [@senateaging](/creator/undefined) [@senrickscott](/creator/undefined) [@sengillibrand](/creator/undefined) [@wsjeditorials](/creator/undefined) [@logicalvaluemx](/creator/undefined) [@petermantas](/creator/undefined) [@biggercapital](/creator/undefined) [@uniqurenv](/creator/undefined) [@robertkennedyjr](/creator/undefined) [@hdatweeting](/creator/undefined) [@realdonaldtrump](/creator/undefined)

**Top assets mentioned**
[uniQure N.V. (QURE)](/topic/$qure) [Abivax SA (ABVX)](/topic/$abvx) [Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [Novartis AG (NVS)](/topic/$nvs) [Olema Pharmaceuticals, Inc. (OLMA)](/topic/$olma) [Insmed, Inc. (INSM)](/topic/$insm) [Janux Therapeutics, Inc. (JANX)](/topic/$janx) [Monte Rosa Therapeutics, Inc. (GLUE)](/topic/$glue) [Eli Lilly and Company (LLY)](/topic/$lly) [Western Digital Corp (WDC)](/topic/$wdc) [Snowflake Inc. (SNOW)](/topic/$snow) [Corcept Therapeutics Inc. (CORT)](/topic/$cort) [Palantir Technologies Inc. (PLTR)](/topic/$pltr) [AppLovin Corporation (APP)](/topic/$app) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Celcuity Inc. Common Stock (CELC)](/topic/$celc) [Pfizer, Inc. (PFE)](/topic/$pfe) [Revolution Medicines, Inc. (RVMD)](/topic/$rvmd) [Merck & Co., Inc. (MRK)](/topic/$mrk)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$qure ($14 to $250 or higher) will outperform $PLTR ($10-180) $app ($60-700) all happening in 18m. Stay tuned"  
[X Link](https://x.com/canoebrookbl/status/1973181205307908304)  2025-10-01T00:20Z [---] followers, [----] engagements


"$qure biotech buyout deal flow continues with JNJ buying $Ptgx and BMS buying Orbital Therapeutics. With a groundbreaking gene therapy for HD a deadly neurodegenerative disease Uniqure will command a much higher premium than recent announced deals"  
[X Link](https://x.com/canoebrookbl/status/1976705156193661171)  2025-10-10T17:43Z [---] followers, [---] engagements


"If $NVS is paying $12B for a phase [--] asset with peak sales forecasts of $2-4B how much will $qure fetch in a buyout $15-20B is a bargain https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline"  
[X Link](https://x.com/canoebrookbl/status/1982497508959084803)  2025-10-26T17:20Z [---] followers, [----] engagements


"$insm I am speechless. What a performance Almost 9x since positive ph [--] brensocatib data but remember the golden rule: 20-25x to 1st peak since positive of 1st major drug 2-3x from current level. One day $qure will become $insm: a $35B co.& beat and raise 10% jump Way to go"  
[X Link](https://x.com/canoebrookbl/status/1983876481718874240)  2025-10-30T12:39Z [---] followers, [----] engagements


"$qure suggest to read his tweet carefully as comments from a discussant. Michael Okun MD: Executive Director of the Fixel Institute for Neurological Diseases at the University of Florida (UF Health) and a leading expert in movement disorders (including HD and Parkinsons) Striking new data were presented from the AMT-130 gene therapy program for Huntingtons disease at the Movement Disorders Society meeting in Hawaii this morning Thanks to Dr. Deborah Hall from Rush for bringing us the breaking data beyond just the press release. This https://t.co/uoRmeHSnqL Striking new data were presented"  
[X Link](https://x.com/canoebrookbl/status/1986689729606393879)  2025-11-07T06:58Z [---] followers, [----] engagements


"$qure UniQure FDA fiasco more heart breaking for these families than investors. Senate hearing and FDA should listen to their stories We need to balance my version of science is the only version with patient access to rare disease medicines/hope https://curehd.blogspot.com/2025/10/as-hopes-build-about-first-effective.htmlm=1 https://curehd.blogspot.com/2025/10/as-hopes-build-about-first-effective.htmlm=1"  
[X Link](https://x.com/canoebrookbl/status/1987206871409971491)  2025-11-08T17:13Z [---] followers, [----] engagements


"$qure $xbi less conservative Bloomberg opinion has similar harsh view on the US FDA. Highlighted toward the end of the article. An intensified media scrutiny from united mainstream media"  
[X Link](https://x.com/canoebrookbl/status/1987302692964958242)  2025-11-08T23:34Z [---] followers, [----] engagements


"After watching the beginning of this MM interview regarding rare disease I think VP will take the hit on HD and $qure and rare disease biological/gene therapy and leave @US_FDA permanently very soon RFK will probably save MM this time. via @YouTube https://youtu.be/-ZKkXlFR8FQsi=Y4JyqoY0Q6woiNOY https://youtu.be/-ZKkXlFR8FQsi=Y4JyqoY0Q6woiNOY"  
[X Link](https://x.com/canoebrookbl/status/1987580068613488704)  2025-11-09T17:56Z [---] followers, [----] engagements


"No VP confirmed thanks @AlecGaffney $crsp CEO is invited. Hopefully MABA will cover @RareDiseases gene therapies like $qure. But this Summit is certainly driving up $xbi and most biotech stocks up Some interesting session titles in the mix here like Makary speaking on the Future of the FDA and a session on making biotech accelerate. Makary tends to bundle policy announcements with big events like this. https://t.co/Nksrk6i9L2 Some interesting session titles in the mix here like Makary speaking on the Future of the FDA and a session on making biotech accelerate. Makary tends to bundle policy"  
[X Link](https://x.com/canoebrookbl/status/1988336919764402473)  2025-11-11T20:03Z [---] followers, [----] engagements


"@LauraLoomer Dear Laura as VP continues to stifle US bio innovation/patient access to innovative gene therapies like AMT-130 by $qure can you use your enormous media influence for the better future of the American people @VPrasadMDMPH https://www.newsweek.com/laura-loomer-fda-vaccine-chief-vinay-prasad-2111358 https://www.newsweek.com/laura-loomer-fda-vaccine-chief-vinay-prasad-2111358"  
[X Link](https://x.com/canoebrookbl/status/1988351390985711746)  2025-11-11T21:01Z [---] followers, [----] engagements


"$olma if you know breast cancer this is the easiest money from $18 post Roche data in less than [--] m. Still has a lot of room to run. JPM TP $55"  
[X Link](https://x.com/canoebrookbl/status/1999580269507150311)  2025-12-12T20:41Z [---] followers, [---] engagements


"$olma NVS or PFE acquisition target in [----] Target market cap$celc"  
[X Link](https://x.com/canoebrookbl/status/2000591103205208188)  2025-12-15T15:37Z [---] followers, [---] engagements


"$glue MRT-8102 data look great. Meaningfully better than canakinumab in terms of CRP reduction and perhaps better and differentiated from NLRP3 inhibitors. CV indication worth$5B but needs8K patients phase [--]. $NVS buyout target. Q is $OLMA first"  
[X Link](https://x.com/canoebrookbl/status/2009113010854613484)  2026-01-08T04:00Z [---] followers, [---] engagements


"$insm BRINSUPRI the beat continues leaving room for future beats. Several clinical milestones this year are also important. Very impressive execution"  
[X Link](https://x.com/canoebrookbl/status/2009632470287937765)  2026-01-09T14:24Z [---] followers, [---] engagements


"$olma buyout next week $NVS or $PFE"  
[X Link](https://x.com/canoebrookbl/status/2009723311337488762)  2026-01-09T20:25Z [---] followers, [---] engagements


"JPM call $rvmd will dominate and $mrk may not be the only bidder. Value could be over $30B if no deal announced this weekend. Smaller deals could be announced during the conference. $olma looks attractive (to NVS PFE) as Roche added about $60 B to its MC since adjuvant BC data"  
[X Link](https://x.com/canoebrookbl/status/2010059030186865108)  2026-01-10T18:39Z [---] followers, [----] engagements


"$insm why does its CEO keep sandbagging Brinsupri launch by not providing guidance Positioning for M&A or they can beat 100-200% each quarter in 2026"  
[X Link](https://x.com/canoebrookbl/status/2012559898790240558)  2026-01-17T16:17Z [---] followers, [---] engagements


"AMT-191 has the best -Gal A enzyme raising data (27-208 fold higher than normal range) in n=4. It is a matter of enrolling more pts and follow up on typical endpoints and FDA interactions. But it is the best pipeline drug for Fabry disease. $qure maybe able to monetize this"  
[X Link](https://x.com/canoebrookbl/status/2018383459669196876)  2026-02-02T17:58Z [---] followers, [----] engagements


"$qure attention is on HD and [---] but [---] generated some interesting data in the most severe type of Fabry disease where unmet need is high. These are classical Fabry disease male patients who do not respond well to ERT. Will have to see lower dose efficacy "  
[X Link](https://x.com/canoebrookbl/status/2019777211180482937)  2026-02-06T14:16Z [---] followers, [----] engagements


"JPM is adding even more than GS. What do they know Waiting for Fidelity"  
[X Link](https://x.com/canoebrookbl/status/2021606295380385837)  2026-02-11T15:24Z [---] followers, [---] engagements


"$cccx will be a steal at $5-6 after President Day"  
[X Link](https://x.com/canoebrookbl/status/2019796693974495317)  2026-02-06T15:33Z [---] followers, [---] engagements


"Can VP survive this time"  
[X Link](https://x.com/canoebrookbl/status/2021723016703652001)  2026-02-11T23:08Z [---] followers, [----] engagements


"@unknown_tester_ You know our friend Peter Marks is a Sr. VP at $lly a not so senior title at one of the BP hard to imagine VP a less senior person than PM is single handedly destroying the whole US pharma/biotech innovations by at least [--] years VP and MM must be gone Let us make it happen"  
[X Link](https://x.com/canoebrookbl/status/2022481645203533923)  2026-02-14T01:22Z [---] followers, [---] engagements


"Check this out Some pretty strong language just in time for patient access to innovative rare disease medicines. Let us see how MM & VP talk the talk but all bad actions https://www.aging.senate.gov/press-releases/chairman-rick-scott-to-convene-hearing-on-fda-regulatory-processes-rare-disease-treatment-delays-and-opportunities-to-improve-patient-access-to-innovation https://www.aging.senate.gov/press-releases/chairman-rick-scott-to-convene-hearing-on-fda-regulatory-processes-rare-disease-treatment-delays-and-opportunities-to-improve-patient-access-to-innovation"  
[X Link](https://x.com/canoebrookbl/status/2023270289241772471)  2026-02-16T05:36Z [---] followers, [----] engagements


"tividenofusp alfa has a placebo controlled double blind phase 2/3 vs standard care ERT (idursulfase). Biomarker plus outcome primary endpoints"  
[X Link](https://x.com/canoebrookbl/status/2020994824699298101)  2026-02-09T22:54Z [---] followers, [---] engagements


"Ironically FDA rare disease day is on 2/23 and then senate hearing on 2/26"  
[X Link](https://x.com/canoebrookbl/status/2023273125291700397)  2026-02-16T05:47Z [---] followers, [---] engagements


"$qure a 5% holder (standard life) adding another 25% of its holdings"  
[X Link](https://x.com/canoebrookbl/status/2012307039058542703)  2026-01-16T23:32Z [---] followers, [----] engagements


"$glue will come back once people realize ziltivekimab has similar potency in hs-CRP reduction (longer duration data) and [--] years ahead with readout later this year. The phase [--] has 7K pts so shooting for a much better HR than canakizumab"  
[X Link](https://x.com/canoebrookbl/status/2010073769340199042)  2026-01-10T19:38Z [---] followers, [---] engagements


"$legn another example of failed strategic review down from $58 in mid [----] to $17 and change now"  
[X Link](https://x.com/canoebrookbl/status/2016721129386496464)  2026-01-29T03:52Z [---] followers, [---] engagements


"$SNYs venglustat failed phase [--] is a big deal. Not much innovation in the non gene therapy area for Fabry disease"  
[X Link](https://x.com/canoebrookbl/status/2018384812986503228)  2026-02-02T18:03Z [---] followers, [---] engagements


"$qure OTM option driven short covering"  
[X Link](https://x.com/canoebrookbl/status/2018708257540386915)  2026-02-03T15:28Z [---] followers, [---] engagements


"$fubo buy at $1.0"  
[X Link](https://x.com/canoebrookbl/status/2018880391399297330)  2026-02-04T02:52Z [---] followers, [---] engagements


"$sgmo got a bit more than [--] m before Nasdaq compliance deadline. Do not think a deal will be done so heading to 1:10 or 1:20 reverse split irreversibly"  
[X Link](https://x.com/canoebrookbl/status/2018884382669611213)  2026-02-04T03:08Z [---] followers, [---] engagements


"Relentless OTM option buying if continues today could drive $qure positive"  
[X Link](https://x.com/canoebrookbl/status/2019071853541683252)  2026-02-04T15:33Z [---] followers, [---] engagements


"At least no one can compound AMT-130 [---] [---] if they are approved someday $Hims is killing $lly and $nvo until it gets sued"  
[X Link](https://x.com/canoebrookbl/status/2019438787798221295)  2026-02-05T15:51Z [---] followers, [---] engagements


"$abvx down day on big index up Potential takeunder lower than current price"  
[X Link](https://x.com/canoebrookbl/status/2019791289043271896)  2026-02-06T15:12Z [---] followers, [---] engagements


"$abvx why is it takeunder When is the CD launch Only 5y composite of matter plus [--] m for US exclusivity. No one is doing BO based on use patent. So obe is pretty much an UC drug currently without maintenance data"  
[X Link](https://x.com/canoebrookbl/status/2019799882786308352)  2026-02-06T15:46Z [---] followers, [---] engagements


"I can see why no pharma wants ST-920 if you have to exclude AAV6 neutralizing ab positive patients that could be half in certain regions and a lot of money to test everyone. L dose [---] seems to have slightly higher a GAL raising potency. Maybe able to monetize soon"  
[X Link](https://x.com/canoebrookbl/status/2020207715482759566)  2026-02-07T18:47Z [---] followers, [---] engagements


"$wdc never too late was in the name since last fall. $WDC and $snow both still a buy. A family member declined post-college finance positions with these two firms last summer. $WDC best performing S&P [---] stock until Friday November [--] https://t.co/06BOe3TDqQ $WDC and $snow both still a buy. A family member declined post-college finance positions with these two firms last summer. $WDC best performing S&P [---] stock until Friday November [--] https://t.co/06BOe3TDqQ"  
[X Link](https://x.com/canoebrookbl/status/2020328787242807578)  2026-02-08T02:48Z [---] followers, [---] engagements


"$qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis"  
[X Link](https://x.com/canoebrookbl/status/1987903479667683634)  2025-11-10T15:21Z [---] followers, 33.1K engagements


"If no confirmatory study is committed then every CBER will say not enough evidence for BLA submission based on phase 1/2 with [--] Y placebo and [--] Y natural history as comparison arm. Briefing book has to be air tight a sentence or a couple of words can derail your filing"  
[X Link](https://x.com/canoebrookbl/status/2023280991151026518)  2026-02-16T06:19Z [---] followers, [---] engagements


"If AK can win a LIV tournament @ [--] by beating Dechambeau and Rahm [--] Y after his last PGA win in [----] the odds of AA for [---] is much much higher We shall see. Only difference is AK won the tournament by himself without a bad referee"  
[X Link](https://x.com/canoebrookbl/status/2023292525264740507)  2026-02-16T07:05Z [---] followers, [---] engagements


"@SenateAging @US_FDA @SenRickScott @SenGillibrand @DrMakaryFDA $xbi $qure$bhvn investors HD SCA rare disease pts/caregivers stay calm and focused if you are in the US speak out and let your voice heard together we keep US biotech innovation moving forward. If you are outside of the US be a little patient and let the US system work"  
[X Link](https://x.com/canoebrookbl/status/1986264459216888166)  2025-11-06T02:48Z [---] followers, [----] engagements


"$qure $bhvn $xbi hot button issues are main topics of the upcoming hearing on the rare disease drug development pipeline regulatory barriers and explore how the FDA can better support innovation while maintaining the highest standards of safety and scientific integrity"  
[X Link](https://x.com/anyuser/status/1986271900876861460)  2025-11-06T03:18Z [---] followers, [----] engagements


"@SenateAging @SenRickScott @US_FDA @SenGillibrand @DrMakaryFDA Senator Scott Gillibrand and Dr. Makary recent FDA rigid approval reviews of gene therapies are inconsistent with the flexibility shown in the draft FDA guideline please insure patient access to rare disease medicines and biotechs continuous commitment to R&D in rare diseases"  
[X Link](https://x.com/canoebrookbl/status/1986320501808189880)  2025-11-06T06:31Z [---] followers, [---] engagements


"$qure important to hear US KOLs like Dr. Ole Isacson who is not a AMT-130 investigators from Science one of the most authoritative journals. His unique academic clinical and industry background adds even more credibility. https://www.science.org/doi/10.1126/science.aec7429 https://www.science.org/doi/10.1126/science.aec7429"  
[X Link](https://x.com/canoebrookbl/status/1986470837822890335)  2025-11-06T16:28Z [---] followers, [----] engagements


"A balanced view but Dr. Henry Miller called AMT-130 a tour de force of delicate brain surgery and molecular biology. These non [---] investigator KOLs opinions weigh heavily on FDA and even senate hearings https://henrymillermd.org/30422/treating-huntingtons https://henrymillermd.org/30422/treating-huntingtons"  
[X Link](https://x.com/canoebrookbl/status/1986507333959360941)  2025-11-06T18:53Z [---] followers, [----] engagements


"$qure strong US (non AMT-130investigator) KOL support A balanced view but Dr. Henry Miller called AMT-130 a tour de force of delicate brain surgery and molecular biology. These non [---] investigator KOLs opinions weigh heavily on FDA and even senate hearings https://t.co/aAwfaYDSTO A balanced view but Dr. Henry Miller called AMT-130 a tour de force of delicate brain surgery and molecular biology. These non [---] investigator KOLs opinions weigh heavily on FDA and even senate hearings https://t.co/aAwfaYDSTO"  
[X Link](https://x.com/canoebrookbl/status/1986526624498786808)  2025-11-06T20:10Z [---] followers, [----] engagements


"$qure Dr. Vinay Prasad Hem/onc disagrees with Drs. Ole Isacson Victor Sung Ed Wild Sarah Tabrizi prof. of Neurology about AMT-130. If you are a HD patient or family members Do you trust a Hem/onc or a Neurology professor"  
[X Link](https://x.com/canoebrookbl/status/1986557400388862413)  2025-11-06T22:12Z [---] followers, [----] engagements


"$qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate"  
[X Link](https://x.com/canoebrookbl/status/1986604355144073317)  2025-11-07T01:19Z [---] followers, 50.3K engagements


"Based on this piece I think someone fairly influential is saying the FDA is on a hot seat and is an embarrassment to the 2nd term of Trumps presidency"  
[X Link](https://x.com/canoebrookbl/status/1986606997735944462)  2025-11-07T01:29Z [---] followers, [----] engagements


"$qure implications: VP replaced AA granted a buyout by an US BP at reasonable (not crazy) premium UniQure is Americanized [---] approved by the FDA ahead of EU/UK victory declared. End of drama $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate. https://t.co/KF9GPCzYNz $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is"  
[X Link](https://x.com/canoebrookbl/status/1986625743892455772)  2025-11-07T02:44Z [---] followers, [----] engagements


"$qure Fidelity close to 10% Vangard (buying) and $jpm (trimming) both close to 2%. All bought most shares after positive data. Senate hearing plus @WSJEditorials piece smacking the US FDA @US_FDA. High stake drama ready to explode and US BP ready to pick up $qure on sale. MAGA"  
[X Link](https://x.com/canoebrookbl/status/1986830925771182220)  2025-11-07T16:19Z [---] followers, [----] engagements


"$qure $xbi not expecting VPs permanent departure [--] days after @WSJEditorials piece smacking @US_FDA last time in July. Worth watching as timeline evolves Time to give rare disease patients hope and access to innovative medicines. US biotech innovation cant be stopped $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate. https://t.co/KF9GPCzYNz $qure WSJ editorial piece sided"  
[X Link](https://x.com/canoebrookbl/status/1986866416159768661)  2025-11-07T18:40Z [---] followers, [----] engagements


"all for AI but do we really want a society in the next x x Ys when your kids do not want to go to colleges b/c a lot of WC jobs are likely replaced by AI and if your loved ones have HD SCA or other rare diseases have nothing not even HOPE $xbi $qure $bhvn. # illustrative"  
[X Link](https://x.com/canoebrookbl/status/1986884665370976427)  2025-11-07T19:53Z [---] followers, [----] engagements


"@US_FDA @RareDiseases $xbi $qure $bhvn after listening to the interview felt even less confident about the FDAs overall credibility and directions. What is your reaction 🔊 Running through the latest batch of National Priority Voucher recipients with Dr. Mundkur. More to come https://t.co/XG28B0PTF4 🔊 Running through the latest batch of National Priority Voucher recipients with Dr. Mundkur. More to come https://t.co/XG28B0PTF4"  
[X Link](https://x.com/canoebrookbl/status/1986945684273299469)  2025-11-07T23:55Z [---] followers, [----] engagements


"$qure after almost [--] m we know [---] data were presented by Dr. Victor Sung at HSG [----] conference in Nashville and by Dr. Deborah Hall at Movement Disorder Society meeting in Hawaii if you find the abstracts and/or presentations please circulate. I did not find them"  
[X Link](https://x.com/canoebrookbl/status/1986957654565228978)  2025-11-08T00:43Z [---] followers, [----] engagements


"$xbi $bhvn $qure rumors or not"  
[X Link](https://x.com/anyuser/status/1987028074614133034)  2025-11-08T05:23Z [---] followers, [----] engagements


"@LogicalValueMx @DesertDweller93 @peter_mantas @biggercapital @uniQure_NV @US_FDA @RobertKennedyJr @HDA_tweeting @realDonaldTrump @VPrasadMDMPH@DrMakaryFDA I think what makes us all angry is this my version of science is the only version because I have power I can override anything even it is beyond my specialty and expertise attitude. Your power is given by all of us THE AMERICAN PEOPLE"  
[X Link](https://x.com/canoebrookbl/status/1987222548086726912)  2025-11-08T18:15Z [---] followers, [----] engagements


"@DesertDweller93 @peter_mantas @biggercapital @uniQure_NV @US_FDA @RobertKennedyJr @HDA_tweeting @realDonaldTrump @LogicalValueMx @VPrasadMDMPH @DrMakaryFDA $qure $xbi http://help4hd.org/speakup4hd @LogicalValueMx @DesertDweller93 @peter_mantas @biggercapital @uniQure_NV @US_FDA @RobertKennedyJr @HDA_tweeting @realDonaldTrump @VPrasadMDMPH@DrMakaryFDA I think what makes us all angry is this my version of science is the only version because I have power I can override anything even it is beyond my specialty and expertise attitude. Your power is given by all of us THE AMERICAN PEOPLE"  
[X Link](https://x.com/canoebrookbl/status/1987226394028540216)  2025-11-08T18:31Z [---] followers, [----] engagements


"$qure similar design to AMT-130: small ph [--] study with external control arm which led to Zolgensma AA and full approval and label extension supported by ph [--] studies. Why dont we get rid of AA and breakthrough therapy entirely and go back to the [--] under this FDA"  
[X Link](https://x.com/canoebrookbl/status/1987299210958676145)  2025-11-08T23:20Z [---] followers, [----] engagements


"@qure $xbi Let us hear from the far left equally harsh on the current FDA last paragraph highlighted the risk of only my version of science is science. Maybe CNN will have a more updated piece next week. https://www.cnn.com/2025/09/12/health/fda-advisory-committee-kff-health-news https://www.cnn.com/2025/09/12/health/fda-advisory-committee-kff-health-news"  
[X Link](https://x.com/canoebrookbl/status/1987319463767908671)  2025-11-09T00:40Z [---] followers, [----] engagements


"$qure I did not read the NYT piece when positive data came out. Reading it now a balanced view with strong support from non [---] investigators. But MM and VP do not need expert opinions. MM can not even pronounce some of the drugs that got his holy grails vouchers"  
[X Link](https://x.com/canoebrookbl/status/1987326642793181612)  2025-11-09T01:09Z [---] followers, [----] engagements


"$qure $nvs $xbi another WSJ editorial board piece taking a jab @VPrasadMDMPH and @US_FDA. This time VP was even incompetent in his own specialty hem/onc by his poor judgement on Pluvicto. Shoutout to @POTUS to intervene directly There is HOPE for HD"  
[X Link](https://x.com/canoebrookbl/status/1987396488113303683)  2025-11-09T05:47Z [---] followers, [----] engagements


"I watched VPs YouTube video criticizing the VISION trial of Pluvicto and encourage you to watch as well. I know how much more you will HATE VP after watching this video given the huge success of Pluvicto. He is truly a disgrace to the @US_FDA"  
[X Link](https://x.com/canoebrookbl/status/1987542311753171364)  2025-11-09T15:26Z [---] followers, [----] engagements


"Lutetium [---] PSMA - Problems with the Vision Trial via @YouTube Imagine what he is doing now with HD and $qure as if he is GOD. but actually knows NOTHING not even in oncology let alone HD and neurology https://youtu.be/pAsPzPt2avcsi=Nv3VnoGCMIznJQvo I watched VPs YouTube video criticizing the VISION trial of Pluvicto and encourage you to watch as well. I know how much more you will HATE VP after watching this video given the huge success of Pluvicto. He is truly a disgrace to the @US_FDA https://t.co/TlCKKNxcYQ https://youtu.be/pAsPzPt2avcsi=Nv3VnoGCMIznJQvo I watched VPs YouTube video"  
[X Link](https://x.com/canoebrookbl/status/1987544349539004783)  2025-11-09T15:34Z [---] followers, [----] engagements


"WSJ Opinion: Hits and Misses of the Week Another blow from WSJ @VPrasadMDMPH this time in video and mentioned VP and $qure. The countdown of VPs demise https://www.wsj.com/video/series/journal-editorial-report/wsj-opinion-hits-and-misses-of-the-week/EDC1EC6D-5214-4DD8-B0E3-738488930277 https://www.wsj.com/video/series/journal-editorial-report/wsj-opinion-hits-and-misses-of-the-week/EDC1EC6D-5214-4DD8-B0E3-738488930277"  
[X Link](https://x.com/canoebrookbl/status/1987680624724099303)  2025-11-10T00:36Z [---] followers, 13.5K engagements


"@adamfeuerstein Agree. I wont be surprised if VP will leave FDA this week given WSJ editorial board three pieces with two specifically attacking VP"  
[X Link](https://x.com/canoebrookbl/status/1987884724866765268)  2025-11-10T14:07Z [---] followers, [----] engagements


"This means advocacy groups and biotech companies can sue the FDA CBER as the relevant underlying legislation the Public Health Service Act doesnt require proof of substantial effectiveness for biologicals. WSJ is not only attacking VP but lay the legal groundwork against him"  
[X Link](https://x.com/canoebrookbl/status/1987904662478205354)  2025-11-10T15:26Z [---] followers, [---] engagements


"$qure investors maybe disappointed by a less feisty call by mgmt I command their poise/willingness to continue to work with the FDA on AA path. With strong support from WSJ why not showing the good side Someone like my post can reach to top legislators directly from both side $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis. https://t.co/H98hVmvLEu $qure pl read this WSJ"  
[X Link](https://x.com/canoebrookbl/status/1987925025215967720)  2025-11-10T16:47Z [---] followers, [----] engagements


"$qure totally possible VP walks back from current FDA stance to keep his job. Assuming he is not too stupid and Robert P. Charrow the previous General Counsel of HHS during the 1st Trump administration gave him some legal advice publicly via WSJ"  
[X Link](https://x.com/canoebrookbl/status/1987936740062228622)  2025-11-10T17:33Z [---] followers, [----] engagements


"$bhvn a bit more challenging for FDA to walk back even with strong support from Tom Philipson former Chairman WH Council of Eco. Advisor in this WSJ piece. $qure is a biological CBER simply does not have any legal ground to deny $qures request for an AA based BLA filing $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis. https://t.co/H98hVmvLEu $qure pl read this WSJ opinion"  
[X Link](https://x.com/canoebrookbl/status/1987986343893627320)  2025-11-10T20:50Z [---] followers, [----] engagements


"$qure I know how much you care about this important information as some of you reached out for clarification of biologicals. Looks like gene therapy should be part of it as Robert answering a readers comment. $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis. https://t.co/H98hVmvLEu $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS"  
[X Link](https://x.com/canoebrookbl/status/1988264335651885213)  2025-11-11T15:15Z [---] followers, [----] engagements


"$qure this WSJ editorial board piece continues to draw significant attention from readers as you can see the number of comments up to today. @US_FDA . You can all get your voices heard directly on WSJ no matter if you are in the US or not. Time to action $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate. https://t.co/KF9GPCzYNz $qure WSJ editorial piece sided with biotech"  
[X Link](https://x.com/canoebrookbl/status/1988268917601816581)  2025-11-11T15:33Z [---] followers, [----] engagements


"$qure an editorial piece on @ScienceMagazine and @Nature by Drs. Ole Isacson and Henry Miller could be as powerful as those WSJ editorial board pieces M.D.s and PhDs time for action @canoebrookbl @US_FDA https://t.co/UgtzZuJJh4 @canoebrookbl @US_FDA https://t.co/UgtzZuJJh4"  
[X Link](https://x.com/anyuser/status/1988273747326026046)  2025-11-11T15:52Z [---] followers, [----] engagements


"$qure once investors realized Robert Charrow former HHS general counsel just gave some serious legal advice to VP/CBER via WSJ and verified with AI research contact with Robert or other legal consultations $qure will be through the roof as the US FDA has no legal ground $qure I know how much you care about this important information as some of you reached out for clarification of biologicals. Looks like gene therapy should be part of it as Robert answering a readers comment. https://t.co/8gg1KZNo4p $qure I know how much you care about this important information as some of you reached out for"  
[X Link](https://x.com/canoebrookbl/status/1988290907716939922)  2025-11-11T17:01Z [---] followers, [----] engagements


"$qure hope you did not all in or emotionally sold at the low You maybe able to recover some of your losses and get paid by the US FDA as even though we do not have all the information looks likely the drop was caused by a flip-flop FDA who has no legal grounds"  
[X Link](https://x.com/canoebrookbl/status/1988303112512434431)  2025-11-11T17:49Z [---] followers, [----] engagements


"$qure $xpi do you see VP on the list Or too small potatoes At hush-hush MAHA summit RFK Jr. and deputies to mix with biotech executives https://t.co/KBmbrrcjQs via @_daniel_payne @ADeAngelis_bio At hush-hush MAHA summit RFK Jr. and deputies to mix with biotech executives https://t.co/KBmbrrcjQs via @_daniel_payne @ADeAngelis_bio"  
[X Link](https://x.com/canoebrookbl/status/1988327644375773613)  2025-11-11T19:27Z [---] followers, [---] engagements


"@AlecGaffney Anything on CBER and VP We all want VP fired or walk back on $qure as he was so incompetent even in oncology as he bashed Pluvictos VISION trial before its approval only to be embarrassed by the success and lifes saved by Pluvicto. VPs science is not the only version of sci"  
[X Link](https://x.com/canoebrookbl/status/1988340585774928320)  2025-11-11T20:18Z [---] followers, [---] engagements


"Rick is a great guy Hope more positive changes on the CBER SIDE. $qure $xbi @LauraLoomer Rick Pazdur moving over to take the reins of CDER is a VERY BIG DEAL for the FDA. It may also be the trigger for more change. Rick Pazdur moving over to take the reins of CDER is a VERY BIG DEAL for the FDA. It may also be the trigger for more change"  
[X Link](https://x.com/canoebrookbl/status/1988358766279225834)  2025-11-11T21:30Z [---] followers, [----] engagements


"$xbi $qure hope VP wont be around at the US FDA to feud with Rick The interpersonal dynamics between CBER's Prasad and CDER's Pazdur are going to be interesting to watch in the coming months as these old posts from Prasad's account (still available) vividly illustrate. https://t.co/lDQT6nygEc The interpersonal dynamics between CBER's Prasad and CDER's Pazdur are going to be interesting to watch in the coming months as these old posts from Prasad's account (still available) vividly illustrate. https://t.co/lDQT6nygEc"  
[X Link](https://x.com/canoebrookbl/status/1988406846181593257)  2025-11-12T00:41Z [---] followers, [----] engagements


"Sonos Hires a Madison Avenue Veteran to Revive Its Bruised Brand - WSJ. $sono back to the initial IPO price. Had Bose before Sonos became popular then fell from grace. Can it recover to the peak What are the new audio gadgets https://www.wsj.com/articles/sonos-hires-a-madison-avenue-veteran-to-revive-its-bruised-brand-5c8e08c0 https://www.wsj.com/articles/sonos-hires-a-madison-avenue-veteran-to-revive-its-bruised-brand-5c8e08c0"  
[X Link](https://x.com/canoebrookbl/status/1988489821241979246)  2025-11-12T06:11Z [---] followers, [---] engagements


"FDA unveils new regulatory roadmap for bespoke drug therapies via @BioPharmaDive $qure did not read it yet is it real https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/ https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/"  
[X Link](https://x.com/canoebrookbl/status/1988755407133929857)  2025-11-12T23:46Z [---] followers, [----] engagements


"$qure it will be quite a bombshell if FDA said no AA but [---] approvable as the 1st one under this MM VP new FDA New Plausible Mechanism Pathway Maybe not as good as AA but you will get an approval. Case solved FDA unveils new regulatory roadmap for bespoke drug therapies https://t.co/C4M1lqmJc7 via @BioPharmaDive $qure did not read it yet is it real FDA unveils new regulatory roadmap for bespoke drug therapies https://t.co/C4M1lqmJc7 via @BioPharmaDive $qure did not read it yet is it real"  
[X Link](https://x.com/anyuser/status/1988783549680607664)  2025-11-13T01:38Z [---] followers, [----] engagements


"$tern has more downside risks now with $elvn positive data even though they have different binding targets. Broadly speaking they are still competitors and $tern is a bit too pricey"  
[X Link](https://x.com/canoebrookbl/status/2009350548026486996)  2026-01-08T19:44Z [---] followers, [---] engagements


"$abvx if they are not stupid should raise another $500 m @100. Obviously no deal near term and they have to get more funding in case no big pharma wants to bite. But this could officially end this fake M&A drama just like $janx a few years ago"  
[X Link](https://x.com/canoebrookbl/status/2009394393787384158)  2026-01-08T22:38Z [---] followers, [----] engagements


"$abvx my call is another $500 m raise post JPM @$100"  
[X Link](https://x.com/canoebrookbl/status/2009657138529161266)  2026-01-09T16:02Z [---] followers, [----] engagements


"$abvx after the interview today if no deal rumor tomorrow stock below $100 after JPM. Missing the window to raise not as smart as $janx to use a so called strategic review to raise 2nd time (which is critical to $janx survival now $janx back to $9 spiked to $90 [--] y ago)"  
[X Link](https://x.com/canoebrookbl/status/2010372993785143526)  2026-01-11T15:27Z [---] followers, [----] engagements


"Looks like Marc missed the raising window not as smart as $janx in [--] m you may need this raise to stabilize $abvx. If placebo adjusted remission is only 20%ish for maintenance not only no buyout but this small co has to commercialize an undifferentiated (but oral) thing"  
[X Link](https://x.com/canoebrookbl/status/2010559425543594418)  2026-01-12T03:48Z [---] followers, [----] engagements


"Double down on strong OS data today. $cort will double towards or after PDUFA in July $cort if it drops to $30 Wolfes PT will add more to my current position bought today. Unless Korlym is losing its patent to Teva in [----] and OS for ROSELLA at final analysis is less robust than at interim I see $cort doubling by mid [----]. https://t.co/QbHtyhvG6d $cort if it drops to $30 Wolfes PT will add more to my current position bought today. Unless Korlym is losing its patent to Teva in [----] and OS for ROSELLA at final analysis is less robust than at interim I see $cort doubling by mid 2026."  
[X Link](https://x.com/canoebrookbl/status/2014433738218995946)  2026-01-22T20:23Z [---] followers, [---] engagements


"$imsr bought this in Dec. and believe it could become a mini $OKLO"  
[X Link](https://x.com/canoebrookbl/status/2014434246753186164)  2026-01-22T20:25Z [---] followers, [---] engagements


"@DesertDweller93 Will short at some point if no buyout. I have high conviction for amt-130 AA but that does not stop me from knowing $qures significant incompetence that is our differences. You have no clue"  
[X Link](https://x.com/canoebrookbl/status/2014723376838017358)  2026-01-23T15:34Z [---] followers, [---] engagements


"Piecing together what $qure management told H.C. Wainwright analyst below and $nvs Votoplam end of ph [--] FDA meeting amt-130 type A meeting will be positive. Board should realize how incompetent current mgmt is and work on a sale quickly. If no buyout post AA $qure is a short $QURE https://t.co/8Uo69Henso $QURE https://t.co/8Uo69Henso"  
[X Link](https://x.com/canoebrookbl/status/2014726507651014838)  2026-01-23T15:46Z [---] followers, [----] engagements


"$abvx still targets $60s by Q1 early Q2. Very much a failed strategic review of an undifferentiated asset. Will see in less than [--] months"  
[X Link](https://x.com/canoebrookbl/status/2015137907607286257)  2026-01-24T19:01Z [---] followers, [----] engagements


"$qure already heard this via $ptct JPM call but good to see in writing from JPM analyst re AA. Sure KOLs can help to design a innovative gene therapy phase [--] to meet confirmatory study requirements. I suggest to include earlier stage HD patients in the confirmatory study"  
[X Link](https://x.com/canoebrookbl/status/2015821859204542550)  2026-01-26T16:19Z [---] followers, [----] engagements


"$cort double down when you need to. Same compelling data no need to test and at 60-70% discount to Immunogen. Oncology alone can be worth twice current MC. Corcepts overall survival data look competitive with AbbVies Elahere and Mercks blockbuster Keytruda Truist Securities said Thursday. #pharma #biospace https://t.co/o7a4IvVtc9 Corcepts overall survival data look competitive with AbbVies Elahere and Mercks blockbuster Keytruda Truist Securities said Thursday. #pharma #biospace https://t.co/o7a4IvVtc9"  
[X Link](https://x.com/canoebrookbl/status/2015826029605212431)  2026-01-26T16:35Z [---] followers, [---] engagements


"$abvx Obe has undifferentiated profiles. Remission rates certainly lower than Rinvoq and JAK inhibitors BBW is overblown. Those CV BBW are for RA no evidence of severe CV risks in IBD. Steroid free and endoscopic remission are concerns as well. TL1A are more disease modifying"  
[X Link](https://x.com/canoebrookbl/status/2015841964638531638)  2026-01-26T17:39Z [---] followers, [----] engagements


"@biotech_jack It has the similar population as Rinvoq. lower efficacy is not disputed with biologicals in the sub population as well"  
[X Link](https://x.com/canoebrookbl/status/2015855601260363834)  2026-01-26T18:33Z [---] followers, [---] engagements


"@biotech_jack Will not have a 1st line label initially. Unfortunately patent is too short If maintenance is competitive re steroid free and endoscopic remission it will be a choice"  
[X Link](https://x.com/canoebrookbl/status/2015874649306046697)  2026-01-26T19:49Z [---] followers, [---] engagements


"@HScottMatusow The briefing book should start with Q1 does the agency support AMT-130 BLA application based on phase 1/2 with [--] Y placebo and [--] Y natural history data for mildly symptomatic stage [--] and [--] HD Then have preclinical clinical safety PK/PD SAP biomarker sections. [--] of 2"  
[X Link](https://x.com/canoebrookbl/status/2016029594688844273)  2026-01-27T06:04Z [---] followers, [--] engagements


"$abvx reiterate this is a failed strategic review and back to $60s before maintenance. Rinvoq has better efficacy and very low CV risks in IBD. IL-23 is dominating with solid safety and efficacy and TL1-a even better efficacy/safety and disease modifying"  
[X Link](https://x.com/canoebrookbl/status/2016576760285188527)  2026-01-28T18:19Z [---] followers, [----] engagements


"$WDC and $snow both still a buy. A family member declined post-college finance positions with these two firms last summer. $WDC best performing S&P [---] stock until Friday November 14"  
[X Link](https://x.com/canoebrookbl/status/1989923452745392372)  2025-11-16T05:08Z [---] followers, [---] engagements


"Do not forget $fold get BO for more than $4B mainly for its Fabry disease drug (a pill)"  
[X Link](https://x.com/canoebrookbl/status/2018386825791066357)  2026-02-02T18:11Z [---] followers, [---] engagements


"Hope $sgmo can monetize ST-920 somehow. No buyout as BP unlikely to pay a premium for a platform yet"  
[X Link](https://x.com/canoebrookbl/status/2018480266478846283)  2026-02-03T00:22Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing